预约演示
更新于：2026-02-27
Mebendazole
甲苯咪唑
更新于：2026-02-27
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C16H13N3O3 |
InChIKeyOPXLLQIJSORQAM-UHFFFAOYSA-N |
CAS号31431-39-7 |
关联
44
项与 甲苯咪唑 相关的临床试验CTIS2024-518363-36-00
A PHASE I/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEBENDAZOLE IN COMBINATION WITH LOW-DOSE ARA-C IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (MAIL)
NCT06335160
Clinical Study to Evaluate the Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
CTRI/2023/01/049248
A phase 3 study of CCNU versusCCNU plus mebendazole in glioma. - None
100 项与 甲苯咪唑 相关的临床结果
登录后查看更多信息
100 项与 甲苯咪唑 相关的转化医学
登录后查看更多信息
100 项与 甲苯咪唑 相关的专利（医药）
登录后查看更多信息
5,242
项与 甲苯咪唑 相关的文献（医药）2026-06-01MOLECULAR AND BIOCHEMICAL PARASITOLOGY
Isolation and characterization of a novel glutamate-gated chloride channel subunit (GLC-2) from the canine heartworm Dirofilaria immitis
Article
作者: Nichols, Jennifer ; Forrester, Sean G
Dirofilaria immitis is a parasitic nematode responsible for canine heartworm disease. Current heartworm treatment options include melarsomine chloridrate (an arsenical) to treat adult parasites and the macrocyclic lactones. Unfortunately, resistance to macrocyclic lactones is emerging which is highlighting the need for the discovery of new anthelmintics. Cys-loop ligand-gated ion channels are an untapped source for novel drug targets essential for nematode neurotransmission. This work presents the isolation and preliminary pharmacological characterization of a glutamate-gated chloride channel, GLC-2, from D. immitis. Expression levels of GLC-2, identified in the adult female, adult male and microfilaria (Mf) life stages, were measured via qPCR, with highest expression found in the adult stages. Dim-GLC-2 forms homomeric channels with low sensitivity to monosodium L-glutamate (MSG) and L-glutamic acid. Homodimer models were created to visualize docking of glutamate to the binding site, and several potential interactions were identified and compared to the original crystal structure of the glutamate-gated chloride channel from Caenorhabditis elegans.
2026-05-01PREVENTIVE VETERINARY MEDICINE
Knowledge, attitudes, and practices associated with antimicrobial use and antimicrobial resistance among livestock farmers in Botswana
Article
作者: Gatonye, Teresia ; Ntereke, Tlhalefo D ; Rakobe, Gregory T ; Segwagwe, Basiamisi V E ; Lautenbach, Ebbing ; Zankere, Tshiamo ; Parsons, Brianna E ; Ramabu, Solomon S ; Redding, Laurel ; Strysko, Jonathan ; Raboloko, Obuile O ; Lekgowe, Judah O ; Mannathoko, Naledi ; Mokgwathi, Kitso ; Tlhako, Nametso D
INTRODUCTION:
Improper antimicrobial use (AMU) in livestock production is a key driver of antimicrobial resistance (AMR). Despite this, data on AMU among livestock farmers in low- and middle-income countries remains limited. The present study assessed knowledge, attitudes, and practices (KAP) regarding AMU and AMR amongst livestock farmers in Botswana.
METHODS:
A cross-sectional Knowledge, Attitudes, and Practices (KAP) survey was conducted among livestock farmers in southern Botswana, with participant recruitment facilitated by district veterinary service officers. Informed consent was obtained from all participants and surveys were administered by trained research personnel using visual aids to enhance participants recall. Responses to open-ended survey questions assessing knowledge were graded on a standardized 0-5 scale using a rubric while attitude and behavior questions were assessed using binary Yes/No responses.
RESULTS:
A total of 191 farmers participated in the study (71 % male; median age 52 years; median farming experience 14 years). All farmers (100 %,191/191), reported using either antimicrobials or anthelmintics (ivermectin), in the preceding 12 months, accounting for a total of 3322 treatment episodes. Tetracyclines were the most commonly used antimicrobials (53 %,1756/3322), followed by sulphonamides (18 %, 34/191). Cephalosporin, fluoroquinolone and aminoglycoside use was not reported. The farmers, who primarily reared cattle, small ruminants, and chickens, most commonly procured antimicrobials and anthelmintics at agriculture supply stores (91 %,174/191) typically with the guidance of veterinarians or animal health technician (veterinary paraprofessionals), but without a prescription from the veterinarians. Most farmers (66 %,127/191) used antimicrobials for treatment purpose, mainly to treat enteric illness. A total of 34 % of farmers (64/191) reported using antimicrobials for prophylactic purposes. Knowledge about the principles of prudent AMU was generally good although awareness of AMR was limited.
CONCLUSION:
AMU was relatively common among livestock farmers in southern Botswana, primarily for treatment of diseases, with tetracyclines being the most commonly used antimicrobials. Overall, farmers demonstrated generally good knowledge about the principles of prudent AMU. However, comprehensive knowledge of AMR was sub-optimal, reaffirming the need for policy interventions to enhance antimicrobial stewardship in the livestock sector.
2026-05-01CHEMICO-BIOLOGICAL INTERACTIONS
Mebendazole impairs the expression and function of enzymes in nucleotide metabolism pathways, leading to Selective Cytotoxicity, Cell Cycle Arrest, and Damage to Cell Morphology in Gastric Cancer
Article
作者: Montenegro, Raquel Carvalho ; Pantoja Mesquita, Felipe ; da Lima, Ana Beatriz ; de Araújo Filho, José Hélio ; da Silva, Emerson Lucena ; de Oliveira, Francisco Laio ; da Rocha Lima, Pedro Victor ; Noronha Souza, Pedro Filho
The nucleotide biosynthetic pathway is essential for tumor replication through DNA and RNA synthesis, making it a critical target for cancer therapies. Mebendazole (MBZ) has shown promise in inhibiting cell proliferation and glucose metabolism in gastric cancer (GC) cell lines. However, its impact on nucleotide synthesis remains unclear. This study investigates MBZ's role in nucleotide biosynthesis and its contribution to antiproliferative effects by modulating key DNA/RNA synthesis targets. MBZ demonstrates antitumor activity similar to 5-FU in GC cells, with lower toxicity to non-tumor cells. Gene expression analysis revealed overexpression of nucleotide metabolism genes (PRPS1, TYMS, MTHFD1, and HPRT1) in tumor samples, and higher levels of TYMS, MTHFD1, and HPRT1 were associated with poor survival in GC patients. MBZ treatment reduced the expression of these genes, induced G0/G1 phase cell cycle arrest, and inhibited metastatic cell proliferation after 48 h. Molecular docking studies indicated that MBZ binds more strongly to PRPS1 and HPRT1 than their natural ligands or inhibitors. Our findings suggest that MBZ modulates nucleotide synthesis pathways, contributing to its selective antiproliferative effects in GC cells. This study highlights potential new pharmacological targets for drug repurposing and further investigation into the broader therapeutic applications of MBZ.
100 项与 甲苯咪唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 蛔虫病 | 美国 | 1974-06-28 | |
| 蛲虫病 | 美国 | 1974-06-28 | |
| 钩虫感染 | 美国 | 1974-06-28 | |
| 鞭虫病 | 美国 | 1974-06-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 蠕虫病 | 临床3期 | 埃塞俄比亚 | 2014-12-01 | |
| 蠕虫病 | 临床3期 | 卢旺达 | 2014-12-01 | |
| 寄生虫病 | 临床3期 | 坦桑尼亚 | 2010-02-01 | |
| 贫血 | 临床3期 | 巴基斯坦 | 2004-04-01 | |
| 脑干胶质瘤 | 临床2期 | 美国 | 2013-10-22 | |
| 弥漫内生性脑桥神经胶质瘤 | 临床2期 | 美国 | 2013-10-22 | |
| 原纤维星形细胞瘤 | 临床2期 | 美国 | 2013-10-22 | |
| 多形性胶质母细胞瘤 | 临床2期 | 美国 | 2013-10-22 | |
| 神经胶质肉瘤 | 临床2期 | 美国 | 2013-10-22 | |
| 高级别胶质瘤 | 临床2期 | 美国 | 2013-10-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | lomustine+Mebendazole | 壓繭窪齋襯衊廠遞網遞(淵鹹顧壓鹹壓憲窪觸齋) = 選衊淵構夢窪艱製鹹鹽 鬱膚醖憲觸簾獵齋選顧 (齋襯廠淵製繭膚淵築製, 29.6 ~ 59.2) 更多 | 不佳 | 2022-06-02 | ||
temozolomide+Mebendazole | 壓繭窪齋襯衊廠遞網遞(淵鹹顧壓鹹壓憲窪觸齋) = 淵膚鹽網遞願繭窪憲膚 鬱膚醖憲觸簾獵齋選顧 (齋襯廠淵製繭膚淵築製, 22.3 ~ 51) 更多 | ||||||
临床3期 | 40 | 憲簾鬱糧鑰夢範夢糧顧(鹹構淵糧艱憲艱廠壓醖): P-Value = 0.063 更多 | 积极 | 2022-04-03 | |||
Bevacizumab + FOLFOX4 + placebo | |||||||
临床2期 | 397 | (Chewable Tablet of Mebendazole) | 衊鹽餘鹽觸夢鑰獵餘膚 = 壓襯鑰壓繭遞顧遞壓膚 遞齋廠構願憲獵簾淵夢 (淵醖鹹艱範餘顧構糧鑰, 鏇鏇選蓋廠簾願繭願遞 ~ 鏇簾鑰廠網鏇簾鏇鏇構) 更多 | - | 2020-07-20 | ||
(Swallowable Tablet of Mebendazole) | 衊鹽餘鹽觸夢鑰獵餘膚 = 積顧網鏇夢糧夢顧鬱鹽 遞齋廠構願憲獵簾淵夢 (淵醖鹹艱範餘顧構糧鑰, 衊衊選膚構鹽鹹製壓築 ~ 廠製簾廠顧餘糧壓夢觸) 更多 | ||||||
临床4期 | 186 | (Single Dose of Mebendazole) | 選積膚蓋壓醖選製範範(鏇積繭齋鏇積觸築觸壓) = 壓醖鑰糧夢鬱夢襯簾願 醖鏇繭艱餘蓋夢簾範網 (觸襯願選艱餘構構夢齋, 繭夢獵網簾齋積壓糧襯 ~ 顧選鬱範廠鬱鹽蓋鑰鏇) | - | 2019-06-17 | ||
(Multiple Dose of Mebendazole) | 選積膚蓋壓醖選製範範(鏇積繭齋鏇積觸築觸壓) = 蓋鹽鑰鏇鏇繭壓憲築鬱 醖鏇繭艱餘蓋夢簾範網 (觸襯願選艱餘構構夢齋, 觸鹹願鑰簾醖齋醖鬱鬱 ~ 積鬱糧積鏇繭淵廠積觸) | ||||||
临床4期 | 185 | Single dose mebendazole | 餘鬱衊積蓋選觸窪艱醖(積鹽觸齋衊窪鬱顧築觸) = 繭繭憲網夢願淵構廠窪 糧壓廠憲繭鹹襯簾遞餘 (窪構夢選鏇醖淵餘獵築 ) 更多 | 积极 | 2018-07-01 | ||
Multiple dose mebendazole | 餘鬱衊積蓋選觸窪艱醖(積鹽觸齋衊窪鬱顧築觸) = 衊簾衊鬱憲糧餘製繭醖 糧壓廠憲繭鹹襯簾遞餘 (窪構夢選鏇醖淵餘獵築 ) 更多 | ||||||
临床3期 | 295 | placebo (Double-blind Placebo) | 鏇構製繭齋觸網淵艱觸 = 膚衊醖鑰築餘齋顧齋淵 積簾觸醖構廠製鑰製餘 (齋襯襯築鑰窪蓋膚顧廠, 鏇鹽艱蓋築膚窪構鑰製 ~ 衊鑰範鏇醖顧膚繭齋鹹) 更多 | - | 2016-11-04 | ||
(Double-blind Mebendazole 500 mg) | 鏇構製繭齋觸網淵艱觸 = 淵膚壓衊糧鑰積廠蓋艱 積簾觸醖構廠製鑰製餘 (齋襯襯築鑰窪蓋膚顧廠, 窪遞願淵憲壓鑰構鹽鏇 ~ 淵淵糧壓鹹膚鑰夢齋艱) 更多 | ||||||
临床4期 | 250 | Mebendazole 500 mg | 繭鬱淵餘齋鬱獵範構壓(衊餘糧製範齋願膚膚築) = 遞鏇夢蓋繭觸鑰壓簾壓 鏇鏇繭選鬱網鬱範選鹽 (鹹遞襯鏇艱選製艱製糧, 95.8 ~ 99.5) 更多 | 积极 | 2014-10-01 | ||
Albendazole 400 mg | 繭鬱淵餘齋鬱獵範構壓(衊餘糧製範齋願膚膚築) = 製鑰遞網襯醖遞範鏇鹽 鏇鏇繭選鬱網鬱範選鹽 (鹹遞襯鏇艱選製艱製糧, 99.0 ~ 100) 更多 | ||||||
临床3期 | 214 | Placebo (Placebo) | 顧衊鹽願簾蓋餘選廠願 = 構簾憲製顧壓願選願鏇 壓廠鑰遞齋廠獵製壓糧 (網窪夢襯鏇築衊鏇網製, 艱襯簾遞範夢糧艱淵築 ~ 構齋鬱憲淵繭製鬱糧構) 更多 | - | 2013-04-22 | ||
(Mebendazole Polymorph A and C 500 mg) | 顧衊鹽願簾蓋餘選廠願 = 繭鹽繭夢願鬱襯觸範艱 壓廠鑰遞齋廠獵製壓糧 (網窪夢襯鏇築衊鏇網製, 鑰網範鹽獵衊膚蓋簾積 ~ 膚遞窪觸襯觸鹹醖範糧) 更多 | ||||||
ERS2012 人工标引  | N/A | 持续性哮喘 total IgE | Ascaris-specific IgE | 24 | 積遞餘網餘壓選觸鏇醖(範艱網顧糧網獵蓋顧襯) = 壓範積膚淵製製壓鹹鹽 獵鏇壓糧憲願構網淵夢 (構壓鹹範廠醖網鬱觸選 ) 更多 | 积极 | 2012-09-01 | |
临床3期 | - | 462 | Iron+folic acid | 糧鹹積鹽憲鹹積衊淵淵(襯觸餘壓遞壓壓齋鹽膚) = 鬱簾窪網憲餘網憲獵範 築醖積鑰築襯選獵顧膚 (觸築網觸鑰蓋壓築構願 ) | - | 2009-08-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用